Correspondence to Dr Hideo Ohuchi, Department of Paediatric Cardiology, National Cerebral and Cardiovascular Centre, 5-7-1, Fujishiro-dai, Suita, Osaka 565-8565, Japan; hohuchi{at}hsp.ncvc.go.jp ...

Abstract: Objective: Current intrapartum fetal monitoring technology is unable to provide physicians with an objective metric of fetal well-being, leading to degraded patient outcomes and increased ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

The final, formatted version of the article will be published soon. Introduction: Wake-promoting agents (WPAs), such as solriamfetol, have emerged as effective treatment options for treating excessive ...

Correspondence to: L M Seccombe Department of Thoracic Medicine, Concord Repatriation General Hospital, Sydney, Australia; seccombelemail.cs.nsw.gov.au Background: Commercial aircraft cabins provide a ...

Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos (mavacamten) in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) has failed to meet its dual primary endpoints. In ...

Investing.com - Barclays has assumed coverage on Cytokinetics (NASDAQ:CYTK) with an Overweight rating and a price target of $87.00, representing 36% upside from the current price of $64.01. The stock ...

1 Newborn Research Centre, The Royal Women's Hospital, Melbourne, Victoria, Australia 2 Neonatal Research, The Murdoch Childrens Research Institute, Melbourne, Victoria, Australia This was a ...

Aortic stenosis is 1 of the most common heart valve diseases among adults. When symptoms develop, prognosis is poor, and current guidelines recommend prompt aortic valve replacement. Depending of the ...

The last 3 decades have seen a revolution in our understanding of the physiology and pathophysiology of iron metabolism in the cardiovascular system. In this review, we highlight the key role of iron ...